Background & Summary
====================

HIV-1 protease mutations responsible for protease inhibitor (PI) resistance are now uncommon in patients with virological failure on an initial PI-containing regimen, particularly regimens including pharmacologically-boosted lopinavir, atazanavir, or darunavir^[@b1]^ One explanation for the infrequent occurrence of PI-resistance mutations in protease is that mutations outside of protease might reduce PI susceptibility even in the absence of primary PI resistance protease mutations. Indeed, many studies have reported that *gag* cleavage and non-cleavage site mutations may compensate for the reduced fitness associated with primary PI-resistance protease mutations^[@b4]^ and several studies of pseudotyped viruses reported that genetic loci in matrix (MA) *gag*^[@b12],[@b13]^ and in the *gp41* cytoplasmic domain (CD)^[@b14]^ can reduce PI susceptibility in the absence of PI-resistance protease mutations.

To identify *gag* and *gp41* mutations under selective PI pressure, we recently sequenced *gag* and/or *gp41* in 61 individuals with virological failure on a PI or a control nonnucleoside RT inhibitor (NNRTI) containing regimen^[@b15]^. We quantified nonsynonymous and synonymous mutations in both genes and identified sites exhibiting signal for directional or diversifying selection. We also used published *gag* and *gp41* polymorphism data to highlight mutations displaying a high selection index, defined as changing from a conserved or common amino acid variant to an uncommon amino acid variant. The rationale for this latter analysis is that most drug-resistance mutations in established targets of antiviral therapy including protease, RT, integrase, and the extracellular domain of *gp41* are amino acid variants at sites that are non-polymorphic in the absence of selective drug pressure.

In our previous study, many amino acid mutations were found to emerge in *gag* and in *gp41*-CD in both the PI- and NNRTI-treated groups. However, in neither gene, were there discernible differences between the two groups in overall numbers of mutations, mutations displaying evidence of diversifying or directional selection, or mutations with a high selection index. Based on this previous study, we concluded that if *gag* and/or *gp41* encoded PI-resistance mutations, they might not be confined to repeated mutations at a few sites, and that multiple studies with large numbers of paired sequences from individuals with virological failure on a PI-containing regimen would need to be pooled to identify such mutations. To facilitate such studies, we provide here a detailed description of the methods used to generate the datasets and analytic results used in our previous study.

The selection index analyses, in particular, require additional exposition because they used data derived from the curation and annotation of *gag* and *gp41* sequences from more than 500 GenBank submission sets and/or peer-reviewed publications to determine the polymorphism rates at each *gag* and *gp41* position. The annotation of these references according to the treatment status of the individuals in the references is included as part of this manuscript's Data Citation. The selection index analyses, also required performing quality control analyses of each *gag* and *gp41* sequence and determining the prevalence of each mutation at each position. Finally, the HyPhy scripts described in this manuscript make it possible to exactly replicate each of the maximum likelihood estimates of the ratio of non-synonymous and synonymous substitution rates presented in our original manuscript.

Methods
=======

*Gag* and *gp41* sequences of paired samples obtained before and after PI or NNRTI therapy
------------------------------------------------------------------------------------------

The sequences described in our previous manuscript were obtained from HIV-1-infected individuals in Northern California who had genotypic resistance tests performed between April 2001 and June 2013 and from participants in the ACTG A5202 clinical trial^[@b3],[@b15]^. The sequences were derived from plasma virus samples obtained before and after therapy from 41 previously PI-naïve subjects who had received a ritonavir-boosted PI-containing regimen or from 20 control subjects who received an NNRTI-containing regimen. Among the 41 PI-treated subjects, paired sequences before and after PI treatment were available for both *gag* and *gp41* in 11 individuals, for *gag* alone in 13 individuals, and for *gp41* alone in 17 individuals. Among 20 NNRTI control subjects, paired sequences before and after NNRTI treatment were available for both *gag* and *gp41* in 13 individuals, for *gag* alone in three individuals, and *gp41* alone in four individuals. [Table 1](#t1){ref-type="table"} (available online only) contains the GenBank accessions for each of the paired protease, *gag* and *gp41* sequences from the 41 PI- and 20 NNRTI-treated individuals. This study was approved by the Institutional Review Boards (IRBs) of Stanford University, KPNC, and the NIH ACTG and all study methods were performed in accordance with the guidelines of these IRBs. Informed consent was required for participation in the ACTG 5202 trial. The Stanford University and KPNC IRBs provided a waiver of informed consent for the study of remnant KPNC samples that were unlinked to individual protected health information.

The plasma samples were processed and underwent direct PCR Sanger sequencing as described in our previous manuscript^[@b15]^. Each *gag*, and *gp41* sequence was aligned using the Translation Align option with the ClustalW algorithm for multiple sequence alignment using the Geneious R11 software^[@b16]^. The parameters used were the default values (cost matrix: BLOSUM; gap open cost: 10; gap extend cost: 0.1). The multiple sequence alignment was then manually edited using the subtype B consensus sequence^[@b17]^. Manual edits were required for the *gag* but not the *gp41* sequence because *gag* contained many more indels than *gp41*. The manual edits were primarily the shifting of indels to be consistent with the remaining sequences and the subtype B consensus. Nucleotide insertions were then stripped from the sequence prior to subsequent analyses.

The original and aligned sets of FASTA sequences for *gag* and *gp41* are in the files gagOriginal.fas, gagAligned.fas, gp41Original.fas, and gp41Aligned.fas (Data Citation 1). The insertions in *gag* and *gp41* are in file insertions.csv. Neighbor-joining trees for each gene, created by HyPhy version 2.3.2 using the TN93 distance, confirmed that each pair of sequences clustered by individual. All trees (in Newick format) are included in Data Citation 1. Data Citation 1 also contains the initial and edited *gag* gene alignments in data/gag.geneious (Data Citation 1).

Pairwise sequence comparisons and dN/dS analyses of *gag* and *gp41*
--------------------------------------------------------------------

[Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"} summarize the median proportions of pairwise nucleotide and amino acid changes, pairwise dN/dS ratios, and median proportions of IUPAC ambiguities in the pre- and post-treatment *gag* and *gp41* sequences, respectively. Pairwise dN/dS ratio estimation was implemented using a custom HyPhy v2.3.2 script scripts/pairwise-estimator-dnds.bf (Data Citation 1); this script reads in a collection of aligned coding sequences, splits them into host pairs (based on patient ID encoded in the FASTA sequence name), and estimates dN/dS by maximum likelihood using the MG94xREV codon substitution model^[@b18]^. The script also optionally restricts the analysis to a contiguous region of the alignment, for example to focus on a specific protein domain.

As noted in the previous manuscript, there was no difference in median proportions of pairwise nucleotide and amino acid changes and pairwise dN/dS ratios in *gag* and *gp41* between the PI- and NNRTI-treated patients. Also, as previously noted, there was a significant reduction in the median proportion of ambiguous nucleotides in *gag* between baseline and follow-up among the PI-treated patients: 0.4% (IQR:0.1% to 0.8%) vs 0.0% (IQR:0% to 0.6%; p=0.02 Mann-Whitney U test). [Table 4](#t4){ref-type="table"} lists each of the amino acid changes that occurred at *gag* cleavage sites.

Positional dN/dS selection analyses of *gag* and *gp41*
-------------------------------------------------------

We ran the fixed effects likelihood (FEL) method, as implemented in HyPhy v2.3.2, to detect codon sites exhibiting diversifying selection in *gag* and *gp41* on the post-treatment branches using a p-value of 0.05 (refs [@b18],[@b19]). This analysis requires annotated phylogenetic trees (e.g., internalFiles/phylo/gagNNRTIs.tre (Data Citation 1)), i.e. trees where post-treatment branches are marked for testing. A convenient tool for annotating trees can be found at <http://phylotree.hyphy.org>. We also used Hyphy v2.3.2 to fit a model of episodic directional selection (MEDS) to the post-treatment branches pressure, also using a p-value of 0.05 (ref. [@b20]). [Table 5](#t5){ref-type="table"} shows the *gag* positions with evidence of diversifying selection and the *gag* mutations with evidence of directional selection within the PI and NNRTI-treatment groups. [Table 6](#t6){ref-type="table"} shows the *gp41* positions with evidence of diversifying selection and evidence of directional selection within the PI and NNRTI-treatment groups. Both of these analyses identify candidate positions and mutations that are most likely to be under selective drug pressure. However, as is the case with any statistical testing procedures, it is possible that some of the positions and/or mutations are misclassified as either false positives or false negatives. Files containing shell scripts are provided to enable users to repeat these selection analyses with the same set of parameters that we used.

Collection of previously published *gag* sequences from ARV-naïve individuals
-----------------------------------------------------------------------------

We downloaded the complete set of 7,550 one-per-person aligned complete *gag* sequences from the Los Alamos National Laboratories (LANL) HIV Sequence Database^[@b21]^. We filtered 565 sequences that contained either large deletions or missing nucleotides (n=238), more than 3 frameshift mutations (n=281), or 3 or more signature APOBEC mutations (n=46) defined as mutations at highly conserved positions that were likely to occur in sequences containing stop codons and that occurred in an appropriate dinucleotide context: GG→AG for APOBEC3G GA→AA for APOBEC3F (ref. [@b22]). Applying the Local FDR Poisson distribution using the R LocFDRPois package to our data, we found that presence of ≥3 signature APOBEC mutations was associated with a 0.99 likelihood of a sequence having undergone APOBEC-mediated G to A hypermutation^[@b23]^. [Table 7](#t7){ref-type="table"} lists the 45 signature APOBEC mutations that we identified and [Fig. 1](#f1){ref-type="fig"} shows the distribution of the number of signature APOBEC mutations per *gag* sequence.

We then used Batch Entrez to submit each of the Accession IDs to GenBank^[@b24]^ and parsed the XML results to aggregate sequences into GenBank submission sets, henceforth referred to as studies, sharing either the same PubMed ID or the same Title and Author List fields. We reviewed the 264 studies reporting three or more individuals. Of these studies, 164 (62.1%) comprised solely ART-naïve individuals, 75 (28.4%) comprised individuals whose treatment status was unknown, and 25 (9.5%) comprised individuals who were ART-experienced. A summary of these 264 studies is provided in gagStudies.csv (Data Citation 1).

We then determined the proportion of each amino acid at each position in *gag* for the complete set of 5,365 one-per-person group M ART-naïve sequences as well as for the four LANL-designated subtypes (A, B, C, and CRF01_AE) for which at least 100 sequences were present. Site-specific amino acids present in 0.1% or fewer sequences were considered unusual. [Fig. 2](#f2){ref-type="fig"} shows that the numbers of *gag* sequences according to the number of unusual mutations per sequence monotonically decreases until n=10 unusual mutations. Therefore, we excluded sequences containing ≥11 unusual mutations since these 27 sequences were considered to be at high risk of poor sequence quality. We then recalculated the proportion of each amino acid at each position for the remaining 5,338 sequences. The original and aligned sets of FASTA sequences for the 5,338 one-per-person filtered sequences from these studies are in gagNaiveOriginal.fas and gagNaiveAligned.fas (Data Citation 1). The header for each sequence contains the GenBank accession number and the LANL-designated subtype. The file gagAAPrevalence.csv (Data Citation 1) lists the proportion of each amino acid at each *gag* position. In this file insertions, deletions, and mixtures are indicated by "ins", "del", and "X", respectively. [Figure 3](#f3){ref-type="fig"} displays the distribution of amino acids at each of the 500 *gag* positions in the one-per-person group M HIV-1 *gag* sequences from ARV-naïve individuals.

Collection of previously published *gp41* sequences from ARV-naïve individuals
------------------------------------------------------------------------------

We downloaded the complete set of 7,489 one-per-person aligned complete *gp41* sequences from the LANL HIV Sequence Database^[@b21]^. We filtered 453 sequences that contained either large deletions or missing nucleotides (n=234), more than 3 frameshift mutations (n=89), or 3 or more signature APOBEC mutations (n=130) defined as mutations at highly conserved positions that were likely to occur in sequences containing stop codons and that occurred in an appropriate dinucleotide context^[@b22]^. Applying the Local FDR Poisson distribution using the R LocFDRPois package to our data, we found that presence of ≥3 signature APOBEC mutations was associated with 0.97 likelihood of a sequence having undergone APOBEC-mediated G to A hypermutation^[@b23]^. [Table 8](#t8){ref-type="table"} lists the 47 signature APOBEC mutations and [Fig. 4](#f4){ref-type="fig"} shows the distribution of the number of signature APOBEC mutations per sequence.

We then used Batch Entrez to submit each of the Accession IDs to GenBank^[@b24]^ and parsed the XML results to aggregate sequences into GenBank submission sets (or studies) sharing either the same PubMed ID or the same Title and Author List fields. We reviewed the 329 studies reporting five or more individuals. Of these studies, 191 (58.1%) comprised solely ART-naïve individuals, 95 (28.9%) comprised individuals whose treatment status was unknown, and 43 (13.0%) comprised individuals who were ART-experienced. A summary of these 329 studies is provided in gp41Studies.csv (Data Citation 1).

We then determined the proportion of each amino acid at each position in *gp41* for the complete set of 4,263 one-per-person group M ART-naïve sequences as well as for each of the four LANL-designated subtypes (A, B, C, and CRF01_AE) for which at least 100 sequences were present. Amino acids occurring at a proportion ≤0.1% were considered unusual. [Figure 5](#f5){ref-type="fig"} shows that the numbers of *gp41* sequences according to the number of unusual mutations per sequence monotonically decreases until n=7 unusual mutations. Therefore, we excluded sequences containing ≥8 unusual mutations, since these 21 sequences were considered to be at high risk of poor sequence quality. We then recalculated the proportion of each amino acid at each position for the remaining 4,242 sequences. The original and aligned sets of sequences for the 4,242 one-per-person filtered sequences from these studies in FASTA format are in gp41NaiveOriginal.fas and gp41NaiveAligned.fas (Data Citation 1). The header for each sequence contains the GenBank accession number and the LANL-designated subtype. The file gp41AAPrevalence.csv (Data Citation 1) lists the proportion of each amino acid at each *gp41* position. In this file insertions, deletions, and mixtures are indicated by "ins", "del", and "X", respectively. [Figure 6](#f6){ref-type="fig"} displays the distribution of amino acids at each of the 345 *gp41* positions in the one-per-person group M HIV-1 *gp41* sequences from ART-naïve individuals.

*Gag* and *gp41* selection indexes
----------------------------------

We used empirical *gag* and *gp41* amino acid site frequencies to calculate a selection index for each amino acid change that developed during therapy defined as follows: log~10~ of the ratio of the proportion of the pre-therapy amino acid in PI-naïve individuals divided by the proportion of the post-therapy amino acid in PI-naïve individuals (fold change). Amino acid changes with a high selection index were defined as changing from a highly conserved or relatively common amino acid variant at a position to an amino acid with a prevalence at least 10 times less common (i.e., a selection index ≥1.0).

The distribution of all selection indexes for *gag* and *gp41* according to treatment was plotted using an R script that accepts as input the list of amino acid changes between pairs of sequences and data on the proportion of each amino acid in an external database. The script and the resulting figures are located at scripts/make-graphical-summary.r, reports/gag-mutations.pdf, and reports/gp41-mutations.pdf (Data Citation 1). As no statistical model for the expected distribution of selection indexes for proteins under selective drug pressure has been developed, the plots are useful primarily for identifying loci at which changes from a conserved to an unusual amino acid were clustered. As noted in our previous manuscript, we found no discernible difference in either *gag* or *gp41* in the distribution of selection indexes between PI- and NNRTI-treated individuals.

Code availability
-----------------

The code used in this manuscript includes the set of Python (version 3.5.2), R (version 3.2.3), and Linux shell scripts that are available on Github (<https://github.com/hivdb/gag-gp41>) and in the gag-gp41.zip file submitted to Dryad Digital Repository (Data Citation 1). The Github site and the Dryad zip file also includes the 24 files cited in this Data Descriptor. There are no restrictions on accessing or using the code or files as they are released under the open source MIT License.

Data Records
============

The original and aligned pre- and post-treatment *gag* and *gp41* sequences from our previous published study are available in four FASTA files in which each sequence header contains four fields: GenBank accession ID, PID, treatment time point, and treatment category (for example KY579846\|118827_PIs_Pre). The sequence files, which are named gagOriginal.fas, gagAligned.fas, gp41Original.fas, and gp41Aligned.fas, are located in the directory data/fasta/ (Data Citation 1). [Table 1](#t1){ref-type="table"} (available online only) lists the GenBank accession IDs according to PID, treatment time point, and treatment category (Data Citation 2, Data Citations 3, Data Citations 4, Data Citations 5, Data Citations 6, Data Citations 7, Data Citations 8, Data Citations 9, Data Citations 10, Data Citations 11, Data Citations 12, Data Citations 13, Data Citations 14, Data Citations 15, Data Citations 16, Data Citations 17, Data Citations 18, Data Citations 19, Data Citations 20). The file data/insertions.csv (Data Citation 1) lists each of the insertions in *gag* and *gp41* as these were removed during sequence alignment. The Newick representation of the neighbour-joining trees for the aligned *gag* and *gp41* sequences are in the directory data/phylo/ (Data Citation 1). [Tables 2](#t2){ref-type="table"}, [3](#t3){ref-type="table"}, and [4](#t4){ref-type="table"} summarize the differences between pre- and post-treatment sequences for *gag*, the *gag* cleavage sites, and *gp41*, respectively.

The Linux shell scripts that pass parameters to Hyphy batch language scripts used to perform the pairwise dN/dS analysis, FEL diversifying selection analysis, and MEDS directional selection analysis are named run-pairwise.sh, run-fel.sh, and run-meds.sh, respectively (Data Citation 1). They are available in the directory scripts/. The summarized results of the pairwise dN/dS analysis are in [Tables 2](#t2){ref-type="table"} and [4](#t4){ref-type="table"}. The results of FEL and MEDS are in [Tables 5](#t5){ref-type="table"} and [6](#t6){ref-type="table"}.

The file data/naiveStudies/gagStudies.csv (Data Citation 1) contains the list of all studies with three or more individuals from whom *gag* sequences were obtained for analyzing mutation prevalence. The files data/naiveStudies/gagNaiveOriginal.fas and data/naiveStudies/gagNaiveAligned.fas (Data Citation 1) contain the 5,338 one-per-person quality-control filtered original and aligned sequences from these studies. [Table 7](#t7){ref-type="table"} lists the *gag* signature APOBEC mutations. [Figure 1](#f1){ref-type="fig"} shows the distribution of the number of *gag* signature APOBEC mutations prior to quality control filtering. [Figure 2](#f2){ref-type="fig"} shows the distribution of the number of unusual amino acids per *gag* sequence. The file gagAAPrevalence.csv (Data Citation 1) lists the proportion of each amino acid at each *gag* position according to HIV-1 subtype in one-per-person sequences filtered for an excess of signature APOBEC mutations and unusual amino acids. report/gag-naive-indels.pdf (Data Citation 1) displays the distribution of insertions and deletions at each position in *gag*. [Figure 3](#f3){ref-type="fig"} displays the proportions of all *gag* amino acid variants present at 1.0% or greater frequency of one-per-person sequences.

The file data/naiveStudies/*gp41*Studies.csv (Data Citation 1) contains the list of all studies with five or more individuals from whom *gp41* sequences were obtained for analyzing mutation prevalence. The files data/naiveStudies/gp41NaiveOriginal.fas and data/naiveStudies/gp41NaiveAligned.fas (Data Citation 1) contain the 4,242 one-per-person quality-control filtered original and aligned sequences from these studies. [Table 8](#t8){ref-type="table"} lists the *gp41* signature APOBEC mutations. [Figure 4](#f4){ref-type="fig"} shows how the distribution of the number of *gp41* signature APOBEC mutations prior to quality control filtering. [Figure 5](#f5){ref-type="fig"} shows the distribution of the number of unusual amino acids per *gp41* sequence. The file gp41AAPrevalence.csv (Data Citation 1) lists the proportion of each amino acid at each *gp41* position according to HIV-1 subtype in one-per-person sequences filtered for an excess of signature APOBEC mutations and unusual amino acids. report/gp41-naive-indels.pdf (Data Citation 1) displays the distribution of insertions and deletions at each position in *gp41*. [Figure 6](#f6){ref-type="fig"} displays the proportions of all *gp41* amino acid variants present in ≥1.0% of one-per-person sequences.

The file scripts/run-basic.py and scripts/make-graphical-summary.r (Data Citation 1) contain the script that accept a list of amino acid changes between pairs of sequences and data on the proportion of each mutation to generate a plot showing the selection indexes for each mutation. The files reports/gag-mutations.pdf, and reports/gp41-mutations.pdf contain the output of these scripts.

Technical Validation
====================

Several concerns arise when calculating positional amino acid prevalence from large numbers of sequences in public databases: (i) Do any of the sequences contain nucleotide sequence errors introduced by those who submitted the sequence?; (ii) Do any of the sequences contain annotation errors introduced by those who submitted the sequence or by database curators?; (iii) Have errors been introduced during sequence alignment resulting in the spurious alignment of nonhomologous positions and secondarily inaccurate mutation proportion data?; and (iv) In the case of HIV-1, do the sequences have evidence of APOBEC-mediated G-to-A hypermutation or other evidence for biological artefact consistent with a nonviable virus protein?

In our analyses, we used the LANL HIV Sequence Database^[@b21]^ to retrieve complete group M HIV-1 *gag* and *gp41* sequences from previously published studies submitted to GenBank^[@b24]^. Despite the fact that GenBank is the standard database for sequences determined by dideoxynucleoside sequencing and that the LANL HIV Sequence Database is a curated HIV sequence database, we performed additional analyses to address the concerns cited in the previous paragraph. This process involved first removing sequences containing large gaps, multiple frame shift mutations, and an excess of signature APOBEC mutations. This was followed by removing a small number of sequences containing high numbers of unusual mutations.

The approach for identifying likely APOBEC-mediated G-to-A hypermutation was similar to an approach that we previously described for HIV-1 protease, RT, and integrase^[@b25]^. We first identified 45 *gag* and 47 *gp41* signature APOBEC mutations. Overall, 23 of the signature mutations were stop codons at positions for which the highly conserved consensus amino acid was tryptophan (W) and 69 were highly unusual amino acids at conserved positions that usually occurred in a sequence containing one or more stop codons. The distribution of the number of signature APOBEC mutations per sequence was then used to exclude a small proportion of sequences with ≥3 signature APOBEC mutations: 0.6% for *gag* and 1.7% for *gp41*.

Following these steps, we plotted the distribution of pairwise uncorrected nucleotide distances for group M HIV-1 *gag* and *gp41* and for those subtypes for which more than 100 sequences were available ([Figs. 7](#f7){ref-type="fig"} and [8](#f8){ref-type="fig"}). The intra- and inter-subtype pairwise distances for both genes clustered around previously reported genetic distances for these genes^[@b26]^. The absence of highly divergent *gag* or *gp41* sequences is consistent with our attention to sequence alignment and sequence quality in creating our curated sequence datasets and amino acid profiles.

We also identified a previous study of *gag* amino acid variation and found that 92.9% (914) of the 984 amino acids which we detected at a prevalence of at least 1.0% of PI-naïve individuals were detected among the 993 amino acids detected at a prevalence of at least 1.0% in this earlier study ^[@b27]^. This previous study was similar in design to ours with the following exceptions: (i) Sequences were obtained from all published studies through 2012 regardless of whether the individuals from whom the sequences were obtained were PI-experienced, PI-naïve, or of uncertain PI treatment history; (ii) Hypermutated sequences were excluded using the Los Alamos Hypermut tool^[@b28]^; and (iii) No isolates were excluded solely on the basis of having a large number of unusual mutations. We did not identify a similarly large study of *gp41* amino acid variation.

The exclusion of outlier sequences is a logical approach to creating useful sequence sets and alignments from which mutation proportion data can be calculated. Nonetheless, highly unusual sequences may not always reflect erroneous or artefactual data. As part of our technical validation pipeline, we have identified those sequences that were excluded should other researchers be interested in their analysis.

Usage Notes
===========

The complete set of files including tables, figures, sequence files, tab-delimited files, and code files are available as a Dryad data citation and on the GitHub repository. The Dryad data citation provides a stable permanent snapshot of the analyses described in this manuscript. The GitHub repository will evolve as new studies are published and as more published studies are reviewed to expand the sets of filtered annotated *gag* and *gp41* sequences from PI-naïve individuals.

Other researchers sequencing *gag* and/or *gp41* sequences before and after PI therapy will be able to pool our data with theirs and to perform the same dN/dS and selection index analyses using the software described in this manuscript and provided on Dryad and GitHub.

Several other aspects of our data and code will be useful to other researchers even if they are not planning to perform the same analyses described in this manuscript: (i) the signature APOBEC mutations for *gag* and *gp41* will be useful for the study of sequences of these two genes; (ii) the *gag* and *gp41* sequence sets, publication summaries, and mutation prevalence files will also be useful to other researchers studying these genes; and (iii) the Hyphy and shell scripts will be useful to other researchers performing dN/dS analyses on sequence pairs. In particular, the HyPhy script for pairwise analysis has not been previously published.
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![Distribution of *gag* APOBEC signature mutations.\
Distribution of the number of APOBEC signature *gag* mutations in the complete set of 7,031 one-per-person, quality-control filtered (i.e. sequences with large numbers of missing nucleotides and frame shifts were excluded) aligned complete *gag* sequences downloaded from the LANL HIV Sequence Database. The 46 sequences containing ≥3 APOBEC signature mutations were considered to be at high risk of having been subject to APOBEC-mediated G-to-A hypermutation and were excluded from our amino acid prevalence calculations.](sdata2018147-f1){#f1}

![Distribution of unusual *gag* mutations.\
Distribution of the number of unusual *gag* amino acids in the 5,365 one-per-person, quality-control and APOBEC-filtered aligned complete *gag* sequences from PI-naïve individuals. Unusual amino acids were defined as those occurring in ≤0.1% of sequences. The 27 sequences containing ≥11 unusual amino acids were removed from the final PI-naïve *gag* amino acid profile.](sdata2018147-f2){#f2}

![Distribution of HIV-1 group M *gag* amino acid variants in sequences from PI-naïve individuals.\
Amino acid variants occurring in 5,338 one-per-person sequences from PI-naïve individuals. Amino acids occurring in ≥50% of sequences are shown in bold black; those occurring in 10 to 49% of sequences are shown in red; and those occurring in 1 to 9% of sequences are shown in blue. Positions at which insertions or deletions have been reported in ≥1% of sequences are indicated by dots. The complete summary of all amino acid variants in group M sequences and for the most common subtypes can be found in the file naiveStudies/gagAAPrevalence.csv (Data Citation 1).](sdata2018147-f3){#f3}

![Distribution of *gp41* APOBEC signature mutations.\
Distribution of the number of *gp41* APOBEC signature mutations in the complete set of 7,166 one-per-person quality-control filtered (i.e. sequences with large numbers of missing nucleotides and frame shifts were excluded) aligned complete *gp41* sequences from the LANL HIV sequence database. The 130 sequences containing ≥3 APOBEC signature mutations were considered to be at high risk of having been subject to APOBEC-mediated G-to-A hypermutation and were excluded from our amino acid prevalence calculations.](sdata2018147-f4){#f4}

![Distribution of unusual *gp41* mutations.\
Distribution of the number of unusual *gp41* amino acids in the 4,263 one-per-person quality-control and APOBEC-filtered aligned complete *gp41* sequences from PI-naïve individuals. Unusual amino acids were defined as those occurring in ≤0.1% of sequences. The 21 sequences containing ≥8 unusual amino acids were removed from the final PI-naïve *gp41* amino acid profile.](sdata2018147-f5){#f5}

![Distribution of HIV-1 group M *gp41* amino acid variants in sequences from PI-naïve individuals.\
Amino acid variants occurring in 4,242 one-per-person sequences from PI-naïve individuals. Amino acids occurring in ≥50% of sequences are shown in bold black; those occurring in 10 to 49% of sequences are shown in red; and those occurring in 1 to 9% of sequences are shown in blue. Positions at which insertions or deletions have been reported in ≥1% of sequences are indicated by dots. The complete summary of all amino acid variants in group M sequences and for the most common subtypes can be found in the file naiveStudies/gp41AAPrevalence.csv (Data Citation 1).](sdata2018147-f6){#f6}

![Distribution of pairwise uncorrected nucleotide distances for 5,338 group M HIV-1 *gag* sequences and within each of the four most common subtypes.\
Approximately 0.001% of group M sequence pairs had distance between 17.5 to 19.6% and cannot be visualized on the figure. The left- and right-sided distributions for the group M sequences reflect intra- and inter-subtype distances, respectively.](sdata2018147-f7){#f7}

![Distribution of pairwise uncorrected nucleotide distances for 4,242 group M HIV-1 *gag* sequences and within each of the four most common subtypes.\
Approximately 0.001% of group M sequence pairs had distance between 20.5 to 21.3% and cannot be visualized on the figure. The left- and right-sided distributions for the group M sequences reflect intra- and inter-subtype distances, respectively.](sdata2018147-f8){#f8}

###### GenBank accessions for each of the paired protease, *gag* and *gp41* sequences

  **Group**   **Subject**   **Protease (PR)**              **Gag**    **Gp41**              
  ----------- ------------- ------------------- ---------- ---------- ---------- ---------- ----------
  PI          8006          KT340026            KT340027   NA         NA         KT339970   KT339971
  PI          14728         KT340028            KT340029   NA         NA         KT339972   KT339973
  PI          14736         GQ210720            GQ213759   NA         NA         KT339974   KT339975
  PI          18380         AY798294            GQ213798   NA         NA         KT339976   KT339977
  PI          24950         KT340030            KT340031   NA         NA         KT339978   KT339979
  PI          25082         GQ210971            GQ212432   NA         NA         KT339980   KT339981
  PI          26307         KT340032            KT340033   KT339954   KT339955   KT339982   KT339983
  PI          38099         KT340034            KT340035   NA         NA         KT339985   KT339984
  PI          39143         KT340036            KT340037   KT339958   KT339959   KT339986   KT339987
  PI          39270         MG171048            MG171049   NA         NA         KY579942   KY579943
  PI          42080         KT340039            KT340040   KT339960   KT339961   KT339988   KT339989
  PI          42654         KT340041            KT340042   NA         NA         KT339990   KT339991
  PI          56120         KT340047            KT340048   KT339966   KT339967   KT339994   KT339995
  PI          56141         KT340049            KT340050   NA         NA         KT339996   KT339997
  PI          57479         KT340051            KT340052   NA         NA         KT339998   KT339999
  PI          118724        MG171059            MG171060   NA         NA         NA         NA
  PI          118745        MG171063            MG171064   KY579860   KY579861   KY579932   KY579933
  PI          118747        MG171065            MG171066   NA         NA         NA         NA
  PI          118754        MG171067            MG171068   NA         NA         NA         NA
  PI          118761        MG171069            MG171070   KY579878   KY579879   NA         NA
  PI          118770        MG171071            MG171072   NA         NA         NA         NA
  PI          118792        MG171073            MG171074   KY579870   KY579871   NA         NA
  PI          118811        MG171075            MG171076   KY579872   KY579873   NA         NA
  PI          118820        MG171077            MG171078   NA         NA         NA         NA
  PI          118823        MG171079            MG171080   KY579864   KY579865   NA         NA
  PI          118827        MG171081            MG171082   KY579846   KY579847   NA         NA
  PI          118828        MG171083            MG171084   KY579854   KY579855   NA         NA
  PI          118840        MG171085            MG171086   NA         NA         KY579940   KY579941
  PI          118846        MG171087            MG171088   KY579880   KY579881   KY579938   KY579939
  PI          118849        MG171089            MG171090   KY579884   KY579885   NA         NA
  PI          118853        MG171091            MG171092   KY579866   KY579867   NA         NA
  PI          118855        MG171093            MG171094   NA         NA         NA         NA
  PI          118856        MG171095            MG171096   NA         NA         KY579944   KY579945
  PI          118860        MG171097            MG171098   KY579848   KY579849   KY579920   KY579921
  PI          118865        MG171099            MG171100   NA         NA         NA         NA
  PI          118870        MG171101            MG171102   NA         NA         NA         NA
  PI          118886        MG171103            MG171104   KY579868   KY579869   NA         NA
  PI          118899        MG171105            MG171106   NA         NA         KY579924   KY579925
  PI          118903        MG171107            MG171108   KY579874   KY579875   KY579936   KY579937
  PI          118905        MG171109            MG171110   NA         NA         NA         NA
  PI          118910        MG171111            MG171112   NA         NA         KY579922   KY579923
  PI          118918        MG171113            MG171114   NA         NA         NA         NA
  PI          118925        MG171115            MG171116   KY579876   KY579877   NA         NA
  PI          118930        MG171117            MG171118   NA         NA         NA         NA
  PI          118934        MG171119            MG171120   NA         NA         NA         NA
  PI          118935        MG171121            MG171122   KY579850   KY579851   KY579928   KY579929
  PI          118942        MG171123            MG171124   NA         NA         NA         NA
  PI          118951        MG171125            MG171126   NA         NA         KY579926   KY579927
  PI          118954        MG171127            MG171128   KY579858   KY579859   NA         NA
  PI          118956        MG171129            MG171130   KY579882   KY579883   NA         NA
  PI          118962        MG171131            MG171132   NA         NA         NA         NA
  PI          118965        MG171133            MG171134   NA         NA         KY579946   KY579947
  PI          118972        MG171135            MG171136   KY579862   KY579863   KY579934   KY579935
  PI          118973        MG171137            MG171138   KY579852   KY579853   KY579930   KY579931
  PI          118982        MG171139            MG171140   NA         NA         NA         NA
  PI          118985        MG171141            MG171142   NA         NA         NA         NA
  PI          118986        MG171143            MG171144   KY579856   KY579857   NA         NA
  NNRTI       8349          GQ206503            MG171044   NA         NA         KY579904   KY579905
  NNRTI       9918          GQ206632            MG171045   KY579838   KY579839   KY579906   KY579907
  NNRTI       25036         GQ210904            MG171046   KY579840   KY579841   KY579908   KY579909
  NNRTI       35596         GQ212974            KY190132   KY579842   KY579843   KY579910   KY579911
  NNRTI       37879         MG171047            KY190134   KY579844   KY579845   KY579912   KY579913
  NNRTI       42036         MG171050            KY190141   KY579814   KY579815   KY579886   KY579887
  NNRTI       42183         MG171051            MG171052   KY579816   KY579817   KY579888   KY579889
  NNRTI       55928         MG171053            MG171054   KY579818   KY579819   KY579890   KY579891
  NNRTI       57448         MG171055            KY190153   NA         NA         KY579914   KY579915
  NNRTI       61483         MG171056            MG171057   NA         NA         KY579916   KY579917
  NNRTI       61631         MG171058            KY190163   NA         NA         KY579918   KY579919
  NNRTI       252392        MG171061            MG171062   KY579832   KY579833   KY579898   KY579899
  NNRTI       264159        KY787124            KY787125   KY579836   KY579837   KY579902   KY579903
  NNRTI       108149        KY787112            KY787113   KY579824   KY579825   NA         NA
  NNRTI       232768        KY787118            KY787119   KY579830   KY579831   NA         NA
  NNRTI       122034        KY787114            KY787115   KY579826   KY579827   KY579894   KY579895
  NNRTI       214046        KY787116            KY787117   KY579828   KY579829   KY579896   KY579897
  NNRTI       21890         KY787108            KY787109   KY579820   KY579821   KY579892   KY579893
  NNRTI       253540        KY787122            KY787123   KY579834   KY579835   KY579900   KY579901
  NNRTI       44969         KY787110            KY787111   KY579822   KY579823   NA         NA

###### Pairwise nucleotide and amino acid changes, dN/dS ratios, and percent ambiguities in HIV-1 *gag* before and after protease inhibitor (PI) and nonnucleoside RT inhibitor (NNRTI) therapy.

                                                                                                      **PI (n=24)**                 **NNRTI (n=16)**    **P**[a](#t2-fn1){ref-type="fn"}
  ------------------------------------------------------------------------------------ ------------------------------------------- ------------------- ----------------------------------
  ***Median % pairwise NA changes (interquartile range)***                                                                                                              
   Complete gene                                                                                     1.1 (0.8--1.6)                  0.6 (0.5--1.3)                   0.1
   Matrix                                                                                            0.4 (0.2--0.6)                  0.2 (0.1--0.6)                   0.1
   C-terminal region                                                                                 0.3 (0.2--0.6)                  0.3 (0.2--0.3)                   0.6
  ***Median % pairwise AA changes (interquartile range)***                                                                                                              
   Complete gene                                                                                     1.4 (0.8--1.8)                  0.8 (0.6--1.2)                   0.1
   Matrix                                                                                            0.6 (0.4--0.6)                  0.4 (0.4--0.9)                   1.0
   C-terminal region                                                                                 0.7 (0.2--0.9)                  0.4 (0.4--0.8)                   0.6
  ***Median pairwise dN/dS ratio (interquartile range)***[b](#t2-fn2){ref-type="fn"}                                                                                    
   Complete gene                                                                                    0.21 (0.08--0.48)               0.35 (0.15--0.57)                 0.2
   Matrix                                                                                           0.24 (0.00--0.68)                0.79 (0.16--∞)                   0.1
   C-terminal region                                                                                0.46 (0.19--1.14)               0.50 (0.24--1.05)                 0.9
  ***Median % IUPAC Ambiguities (interquartile range)***[c](#t2-fn3){ref-type="fn"}                                                                                     
   Baseline (complete gene)                                                             0.4[c](#t2-fn3){ref-type="fn"} (0.1--0.8)    0.1 (0.1--0.1)                   0.1
   Follow-up (complete gene)                                                            0.0[c](#t2-fn3){ref-type="fn"} (0.0--0.6)    0.0 (0.0--0.1)                   0.2

^a^Mann-Whitney U Test.

^b^Ratio of nonsynonymous to synonymous mutations.

^c^The proportion of ambiguities (i.e., mixtures of more than one base at the same position) was significantly higher at baseline than at follow-up in the PI group (p=0.02; Mann-Whitney U Test).

###### Pairwise nucleotide and amino acid changes, dN/dS ratios, and percent ambiguities in HIV-1 *gp41* before and after protease inhibitor (PI) and nonnucleoside inhibitor (NNRTI) therapy.

                                                                                          **PI (n=28)**     **NNRTI (n=17)**    **P**[a](#t3-fn1){ref-type="fn"}
  ------------------------------------------------------------------------------------ ------------------- ------------------- ----------------------------------
  ***Median % pairwise NA changes (interquartile range)***                                                                                      
   Complete gene                                                                         1.1 (0.5--1.5)      0.8 (0.6--1.4)                   0.8
   Cytoplasmic domain                                                                    0.4 (0.3--0.9)      0.6 (0.2--0.7)                   1.0
  ***Median % pairwise AA changes (interquartile range)***                                                                                      
   Complete gene                                                                         1.4 (0.6--2.2)      1.3 (0.9--2.2)                   0.7
   Cytoplasmic domain                                                                    0.9 (0.3--1.4)      0.9 (0.6--1.1)                   0.9
  ***Median pairwise dN/dS ratio (interquartile range)***[b](#t3-fn2){ref-type="fn"}                                                            
   Complete gene                                                                        0.42 (0.16--0.74)   0.44 (0.29--0.96)                 0.4
   Cytoplasmic domain                                                                   0.59 (0.17--1.99)   0.47 (0.32--0.93)                 0.9
  ***Median % IUPAC Ambiguities (interquartile range)***                                                                                        
   Baseline (complete gene)                                                              0.1 (0.0--0.2)      0.1 (0.0--0.1)                   0.8
   Follow-up (complete gene)                                                             0.0 (0.0--0.1)      0.0 (0.0--0.1)                   0.4

^a^Mann-Whitney U Test.

^b^Ratio of nonsynonymous to synonymous mutations.

###### Amino acid changes occurring within protease cleavage sites in *gag* during protease inhibitor (PI) and nonnucleoside RT inhibitor (NNRTI) therapy.

  **Cleavage site**                                      **Position**     **Baseline AAs**                                        **Follow-up AAs**            **\# patients**
  -------------------------------------------------- -------------------- ------------------------------------------------------- ---------------------------- -----------------
  ***PI group***                                                                                                                                                
  SP1 / Nucleocapsid (NC)                                    373          [I]{.ul}PAAM\|MQRGN                                     [M]{.ul}PAAM\|MQRGN          1
                                                             373          [P]{.ul}TAIM\|MQKGN                                     [S]{.ul}TAIM\|MQKGN          1
                                                           373, 375       [S]{.ul}T[A]{.ul}IM\|MQKGN                              [P]{.ul}T[T]{.ul}IM\|MQKGN   1
                                                           374, 380       P[X]{.ul}AIM\|MQ[K]{.ul}GN[a](#t4-fn1){ref-type="fn"}   P[P]{.ul}AIM\|MQ[R]{.ul}GN   1
                                                           374, 381       S[A]{.ul}AMM\|MQR[S]{.ul}N                              S[T]{.ul}AMM\|MQR[G]{.ul}N   1
                                                             374          S[X]{.ul}AIM\|MQKGN[a](#t4-fn1){ref-type="fn"}          S[T]{.ul}AIM\|MQKGN          1
                                                           375, 378       SA[N]{.ul}IM\|[M]{.ul}QRGN                              SA[A]{.ul}IM\|[I]{.ul}QRGN   1
                                                           376, 380       SAT[I]{.ul}M\|MQ[K]{.ul}GN                              SAT[T]{.ul}M\|MQ[R]{.ul}GN   1
                                                             378          SASVM\|[M]{.ul}QRGN                                     SASVM\|[I]{.ul}QRGN          1
  Nucleocapsid (NC) / SP2                                  429, 436       E[K]{.ul}QAN\|FLG[R]{.ul}I                              E[R]{.ul}QAN\|FLG[K]{.ul}I   1
                                                             436          ERQAN\|FLG[K]{.ul}L                                     ERQAN\|FLG[R]{.ul}L          1
                                                             436          ERQAN\|FLG[X]{.ul}I[a](#t4-fn1){ref-type="fn"}          ERQAN\|FLG[K]{.ul}I          1
                                                             437          ERQAN\|FLGK[X]{.ul}[a](#t4-fn1){ref-type="fn"}          ERQAN\|FLGK[L]{.ul}          1
  SP2 / p6^*g*^[a](#t4-fn1){ref-type="fn"}^*g*^              453          RPGNF\|LQSR[L]{.ul}                                     RPGNF\|LQSR[P]{.ul}          2
  p6^*pol*^ / Protease[b](#t4-fn2){ref-type="fn"}     485, 486, 487, 490  V[XLX]{.ul}F\|P[X]{.ul}ITL[a](#t4-fn1){ref-type="fn"}   V[SFS]{.ul}F\|P[Q]{.ul}ITL   1
                                                             486          VS[V]{.ul}NF\|PQITL                                     VS[L]{.ul}NF\|PQITL          1
  ***NNRTI group***                                                                                                                                             
   Matrix (MA) / Capsid (CA)                                 132          VSHN[Y]{.ul}\|PIVQN                                     VSHN[F]{.ul}\|PIVQN          1
   SP1 / Nucleocapsid (NC)                                   374          \-[S]{.ul}TAM\|MQRGN                                    \-[T]{.ul}TAM\|MQRGN         1
                                                             374          P[T]{.ul}TIM\|MQRGN                                     P[A]{.ul}TIM\|MQRGN          1
                                                             375          PA[A]{.ul}IM\|MQRGN                                     PA[T]{.ul}IM\|MQRGN          1
                                                             375          SA[A]{.ul}IM\|MQKGN                                     SA[N]{.ul}IM\|MQKGN          1
                                                             375          ST[A]{.ul}IM\|MQRGN                                     ST[T]{.ul}IM\|MQRGN          1
   Nucleocapsid (NC) / SP2                                   429          E[K]{.ul}QAN\|FLGRL                                     E[R]{.ul}QAN\|FLGRL          1
   SP2 / p6^*g*^[a](#t4-fn1){ref-type="fn"}^*g*^             453          RPGNF\|PQSR[L]{.ul}                                     RPGNF\|PQSR[P]{.ul}          1
   p6^*pol*^ / Protease[b](#t4-fn2){ref-type="fn"}           487          VSF[S]{.ul}F\|PQITL                                     VSF[N]{.ul}F\|PQITL          1
                                                             488          VSLD[L]{.ul}\|PQITL                                     VSLD[F]{.ul}\|PQITL          1

^a^X stands for mixtures consisted of at least two amino acids which were not subtype B consensus.

^b^A -1 frameshift was applied to the *pol* reading frame relative to the *gag* reading frame.

###### Amino acid positions with evidence of diversifying selection and mutations with evidence of directional selection in HIV-1 *gag* within the protease inhibitor (PI) and nonnucleoside RT inhibitor (NNRTI)-treatment groups.

  ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------
  ***Positions with Evidence of Diversifying Selection (FEL)***[a](#t5-fn1){ref-type="fn"}                                                        
   PI                                                                                                         67 (0.04), 115 (0.05), 223 (0.008), 468 (0.03), 469 (0.008), 474 (0.03)
   NNRTI                                                                                                                          54 (0.04), 69 (0.03), 173 (0.04)
  ***Mutations with Evidence of Directional Selection (MEDS)***[b](#t5-fn2){ref-type="fn"}                                                        
   PI                                                                                         K59M (1, p=0.000), Q219H (3, p=0.000)[c](#t5-fn3){ref-type="fn"}, F370Y (1, p=0.000), T371N (1, p=0.001)
   NNRTI                                                                                                   Y79F (2, p=0.000), K110M (1, p=0.001), A371T (1, p=0.001), N371T (1, p=0.001)
  ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------

^a^Parentheses contain p-values.

^b^Parentheses contain number of individuals and p-values.

^c^In one individual, there was a change from H219→Q.

###### Amino acid positions with evidence of diversifying selection and the mutations with evidence of directional selection in HIV-1 *gp41* within the protease inhibitor (PI) and nonnucleoside RT inhibitor (NNRTI)-treatment groups.

  ------------------------------------------------------------------------------------------ ------------------------------------------------------------
  ***Positions with Evidence of Diversifying Selection (FEL)***[a](#t6-fn1){ref-type="fn"}                                 
   PI                                                                                                     55 (0.02), 101 (0.01), 273 (0.02)
   NNRTI                                                                                                  24 (0.009), 187 (0.04), 310 (0.04)
  ***Mutations with Evidence of Directional Selection (MEDS)***[b](#t6-fn2){ref-type="fn"}                                 
   PI                                                                                         T307I (3, p=0.001), I325F (1, p=0.001), L325F (1, p=0.001)
   NNRTI                                                                                                                 None
  ------------------------------------------------------------------------------------------ ------------------------------------------------------------

^a^Parentheses contain p-values.

^b^Parentheses contain number of individuals and p-values.

###### HIV-1 *gag* signature APOBEC mutations[a](#t7-fn1){ref-type="fn"}.

   **Position**  **Consensus AA**[b](#t7-fn2){ref-type="fn"}    **Consensus %**[b](#t7-fn2){ref-type="fn"}   **Signature mutation**[c](#t7-fn3){ref-type="fn"}   **Proportion occurring in sequence with a stop codon**   **\# Sequences with mutation**
  -------------- --------------------------------------------- -------------------------------------------- --------------------------------------------------- -------------------------------------------------------- --------------------------------
        1        M                                                                 98.9                                              I                                                     89                                           36
        16       W                                                                 98.7                                             \*                                                    100                                           31
        24       G                                                                 99.2                                              E                                                     53                                           17
        25       G                                                                 99.2                                              R                                                     71                                           7
        36       W                                                                 99.6                                             \*                                                    100                                           15
        56       G                                                                 99.9                                              R                                                     60                                           5
        71       G                                                                 99.5                                              R                                                     75                                           4
        99       E                                                                 99.3                                              K                                                     67                                           6
       140       G                                                                 99.8                                              E                                                    100                                           1
       140       G                                                                 99.8                                              R                                                     82                                           11
       155       W                                                                 99.5                                             \*                                                    100                                           31
       192       G                                                                 99.8                                              E                                                     60                                           5
       192       G                                                                 99.8                                              R                                                     90                                           10
       212       W                                                                 99.4                                             \*                                                    100                                           33
       214       R                                                                 99.8                                              K                                                     58                                           12
       221       G                                                                 99.9                                              R                                                     78                                           9
       229       R                                                                 99.6                                              K                                                     67                                           18
       232       R                                                                 99.1                                              K                                                     60                                           25
       233       G                                                                 99.8                                              R                                                    100                                           5
       249       W                                                                 99.5                                             \*                                                    100                                           22
       265       W                                                                 99.6                                             \*                                                    100                                           25
       269       G                                                                 99.7                                              R                                                     80                                           15
       284       D                                                                 99.5                                              N                                                    100                                           3
       288       G                                                                 99.6                                              R                                                     88                                           24
       294       R                                                                 99.7                                              K                                                     67                                           15
       298       D                                                                 99.8                                              N                                                     67                                           3
       299       R                                                                 99.8                                              Q                                                    100                                           5
       305       R                                                                 99.8                                              K                                                     67                                           6
       316       W                                                                 99.5                                             \*                                                    100                                           31
       338       G                                                                 99.7                                              R                                                     53                                           19
       352       G                                                                 99.8                                              R                                                     71                                           7
       354       G                                                                 99.8                                              R                                                     70                                           10
       355       G                                                                 99.9                                              R                                                     60                                           5
       365       E                                                                 99.8                                              K                                                    100                                           2
       396       G                                                                 100                                               S                                                    100                                           2
       399       G                                                                 99.7                                              R                                                     71                                           17
       414       W                                                                 99.3                                             \*                                                    100                                           31
       417       G                                                                 99.4                                              R                                                     71                                           24
       420       G                                                                 99.7                                              E                                                     67                                           6
       420       G                                                                 99.7                                              R                                                     62                                           8
       435       G                                                                 99.3                                              R                                                     72                                           29
       438       W                                                                 99.5                                             \*                                                    100                                           4
       443       G                                                                 98.8                                              R                                                     60                                           10
       446       G                                                                 99.4                                              E                                                     60                                           10
       446       G                                                                 99.4                                              R                                                     76                                           21

^a^Mutations at highly conserved positions that are likely to occur in sequences with stop codons and that occur in an appropriate dinucleotide context: GG→AG or GA→AA.

^b^Amino acid present in \>97.5% of Group M HIV-1 sequences.

^c^Mutations strongly consistent with APOBEC-mediated G-to-A hypermutation. "\*": stop codon.

###### HIV-1 *gp41* signature APOBEC mutations[a](#t8-fn1){ref-type="fn"}.

   **Position**  **Consensus AA**[b](#t8-fn2){ref-type="fn"}    **Consensus %**[b](#t8-fn2){ref-type="fn"}   **Signature mutation**[c](#t8-fn3){ref-type="fn"}   **Proportion occurring in sequence with a stop codon**   **\# Sequences with mutation**
  -------------- --------------------------------------------- -------------------------------------------- --------------------------------------------------- -------------------------------------------------------- --------------------------------
        5        G                                                                 98.4                                              R                                                     87                                           39
        10       G                                                                 98.3                                              R                                                     90                                           69
        16       G                                                                 99.2                                              E                                                     62                                           13
        16       G                                                                 99.2                                              R                                                     83                                           35
        19       M                                                                 98.6                                              I                                                     93                                           95
        36       G                                                                  99                                               R                                                    100                                           5
        36       G                                                                  99                                               S                                                     93                                           44
        60       W                                                                 98.5                                             \*                                                    100                                          103
        61       G                                                                 99.4                                              S                                                     83                                           6
        68       R                                                                 99.5                                              K                                                     92                                           25
        73       E                                                                 99.4                                              K                                                     69                                           32
        78       D                                                                 99.3                                              N                                                     83                                           18
        83       G                                                                 98.5                                              E                                                     71                                           7
        83       G                                                                 98.5                                              R                                                     86                                           58
        85       W                                                                 98.4                                             \*                                                    100                                          100
        86       G                                                                 99.7                                              R                                                    100                                           1
        86       G                                                                 99.7                                              S                                                     93                                           15
        89       G                                                                 98.1                                              E                                                     65                                           20
        89       G                                                                 98.1                                              R                                                     91                                           70
        99       W                                                                 98.4                                             \*                                                    100                                          102
       103       W                                                                 98.6                                             \*                                                    100                                           93
       112       W                                                                 98.3                                             \*                                                    100                                          107
       117       W                                                                 98.5                                             \*                                                    100                                           99
       120       W                                                                 98.2                                             \*                                                    100                                          117
       146       E                                                                 99.2                                              K                                                     55                                           40
       155       W                                                                 98.7                                             \*                                                    100                                           85
       159       W                                                                 98.3                                             \*                                                    100                                           99
       161       W                                                                 98.6                                             \*                                                    100                                           87
       167       W                                                                 99.3                                             \*                                                    100                                           41
       169       W                                                                 98.2                                             \*                                                    100                                           66
       179       G                                                                 97.6                                              E                                                     57                                           7
       179       G                                                                 97.6                                              R                                                     96                                           54
       180       G                                                                 98.2                                              R                                                    100                                           2
       183       G                                                                 98.4                                              R                                                     69                                           16
       183       G                                                                 98.4                                              S                                                     83                                           60
       200       G                                                                 98.7                                              E                                                     60                                           15
       200       G                                                                 98.7                                              R                                                     90                                           69
       227       G                                                                 98.8                                              E                                                     79                                           19
       227       G                                                                 98.8                                              R                                                     90                                           48
       240       G                                                                 98.1                                              E                                                     75                                           12
       240       G                                                                 98.1                                              R                                                     82                                           72
       246       W                                                                 98.2                                             \*                                                    100                                          110
       248       D                                                                 99.7                                              N                                                     82                                           11
       269       R                                                                 98.3                                              K                                                     57                                           53
       292       W                                                                 97.8                                             \*                                                    100                                          108
       339       G                                                                 99.1                                              S                                                     65                                           34
       341       E                                                                  99                                               K                                                     55                                           53

^a^Mutations at highly conserved positions that are likely to occur in sequences with stop codons and that occur in an appropriate dinucleotide context: GG→AG or GA→AA.

^b^Amino acids present in \>97.5% of Group M HIV-1 sequences.

^c^Mutations strongly consistent with APOBEC-mediated G-to-A hypermutation. "\*": stop codon.

[^1]: P.L.T. performed the analyses and wrote the software described in the manuscript. S.-Y.R. assisted with several of the analyses described in the manuscript. S.L.K.P. developed the original dN/dS analyses, assisted with how these analyses were implemented and described, and assisted in writing the manuscript. J.M. generated the majority of the sequence data described in the original analysis. R.W.S. conceived of the study and wrote the manuscript.
